Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

RATED: Mdys/S&P/Fitch rate CAB sr sec B2/B-/B+, Laboratoire Eimer sr notes Caa1/CCC/CCC+

HYC European Market: Deal Flow - General

Moody's/S&P/Fitch rate Biogroup EUR1bn 144A/Reg S 2-part - CAB EUR750m sr sec notes due 2028 (7y) B2/B-/B+ (negative/stable/stable); and Laboratoire Eimer EUR250m sr notes due 2029 (8y) Caa1/CCC/CCC+ (negative/stable/stable). Via JPM+. Fitch also revised the outlook to stable from negative

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.